NSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.
Marksans Pharma Ltd: key numbers
- Share price
- ₹306.20
- Market cap
- ₹13,876 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 26.9×Sector 45.9×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Marksans Pharma Other Announcement
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Marksans Pharma Promoter Selling (Off-Market)
Director Sandra Saldanha gifted 2,28,273 shares of Marksans Pharma Ltd to her daughters in an off-market transaction. This internal transfer reallocates promoter-group equity holdings.
Marksans Pharma Other Announcement
Marksans Pharma intimated shareholders about SEBI's extended special window (Feb 2026–Feb 2027) for re-lodgement of pre-April-2019 physical share transfer deeds. No new business, capital, or operational event is disclosed.
Marksans Pharma Annual General Meeting
Marksans Pharma Limited conducted its 34th Annual General Meeting on August 27, 2026. Shareholders considered the adoption of FY2025-26 financial statements and a dividend of Rs. 0.90 per share.
Marksans Pharma Other Announcement
Marksans Pharma Ltd. has received an ESG score of 56 from Crisil ESG Ratings & Analytics Ltd for Fiscal 2026.
Other board meeting outcome announcements
All →VCU Data Management Board Meeting Outcome
VCU Data Management appointed M/s. Utkarsh Shah & Co. as Secretarial Auditors for five years from FY 2026-27, subject to AGM approval. No monetary amount is disclosed, so this is an auditor appointment intimation.
- Execution
- FY 2026-27 to 2030-31 (five years)
Hardcastle & Waud Manufacturing Company Board Meeting Outcome
The board revoked its earlier Mumbai office shift and approved moving the registered office to Mira Road, Thane. The change awaits shareholder and regulatory approval.
Greenply Industries Board Meeting Outcome
Greenply appoints MSKA & Associates LLP as statutory auditor for five years from the 2027 AGM, subject to shareholder approval. Incumbent BSR & Co. continues until then.
- Execution
- 5 years, from the conclusion of the 37th AGM (2027) to the conclusion of the 42nd AGM (2032)
Greaves Cotton Board Meeting Outcome
Greaves Cotton confirmed its Board met on October 29, 2026, on unaudited half-year results. No new financial figures are disclosed in this filing.
Popular Vehicles and Services Board Meeting Outcome
Popular Vehicles passed a circular resolution approving a routine AOA amendment on the common seal. A postal ballot notice and scrutinizer were also appointed.
R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.